Picture of N4 Pharma logo

N4P N4 Pharma News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

REG - AIM - AIM Notice - 24/11/2022

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221124:nRSX4025Ha&default-theme=true

RNS Number : 4025H  AIM  24 November 2022

NOTICE

 

24/11/2022 - 08:00

 

The London Stock Exchange admits the following securities to trading on AIM:

 

 AMAROQ MINERALS LTD.                                        BLOCK ADMISSION
 9,437,395    COMMON SHARES OF NO PAR VALUE FULLY PAID (DI)  (BPLH6M8)(CA02312A1066)

 

 ANGUS ENERGY PLC
 312,000  ORDINARY SHARES OF GBP0.002 EACH FULLY PAID  (BYWKC98)(GB00BYWKC989)

 

 AURA ENERGY LIMITED
 505,000  ORDINARY SHARES OF NO PAR VALUE FULLY PAID (DI)  (BD1RHP4)(AU000000AEE7)

 

 ERGOMED PLC
 40,000  ORDINARY SHARES OF 1P EACH FULLY PAID  (BN7ZCY6)(GB00BN7ZCY67)

 

 JUBILEE METALS GROUP PLC
 4,659,599  ORDINARY SHARES OF 1P EACH, FULLY PAID  (3185216)(GB0031852162)

 

 LEARNING TECHNOLOGIES GROUP PLC
 108,125  ORDINARY SHARES OF 0.375P EACH FULLY PAID  (B4T7HX1)(GB00B4T7HX10)

 

 N4 PHARMA PLC
 50,000,000  ORDINARY SHARES OF 0.4P EACH, FULLY PAID  (BYW8QM3)(GB00BYW8QM32)

 

 NORTHCODERS GROUP PLC
 744,444  ORDINARY SHARES OF GBP0.01 EACH FULLY PAID  (BL97B94)(GB00BL97B942)

 

 TIALIS ESSENTIAL IT PLC
 104,000  ORDINARY SHARES OF 1P EACH, FULLY PAID  (BN4M3M5)(GB00BN4M3M55)

 

AMENDMENT

 

Following a Capital Reorganisation the following security has been amended:

 

 INVINITY ENERGY SYSTEMS PLC
   ORDINARY SHARES OF EUR0.50 EACH, FULLY PAID  (BLR94N7)(JE00BLR94N79)

 

This should appear as:

 

 INVINITY ENERGY SYSTEMS PLC
   ORDINARY SHARES OF EUR0.01 EACH, FULLY PAID  (BLR94N7)(JE00BLR94N79)

 

If you have any queries or require further information, please contact Market
Operations on 020 7797 4310.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AMOBLBDBGDDDGDX

Recent news on N4 Pharma

See all news